Bildkälla: Stockfoto

SynAct Pharma: Rights Issue Oversubscribed - Redeye

Redeye comments on SynAct’s successful rights issue.

Redeye comments on SynAct’s successful rights issue.
Börsvärldens nyhetsbrev
ANNONSER